Vermillion issued U.S. patent for method to aid diagnosis of nephrotic syndrome

Vermillion, Inc. has announced that the United States Patent Office (USPTO) has issued Vermillion U.S. Patent No. 7,297,556 for aiding diagnosis of nephrotic syndrome, a kidney disorder marked by very high or low levels of protein in the urine, which results in bodily swelling and high cholesterol.

Nephrotic syndrome is most commonly caused by complications from chronic diabetes or kidney disease. (i)

"The issuance of this patent is another testament to Vermillion's novel molecular diagnostic technological approach of applying protein biomarkers to aid in the diagnosis and management of serious, life-threatening diseases," said Gail S. Page, Chief Executive Officer of Vermillion, Inc. "We plan to capitalize on our intellectual property as it grows for the benefit of patients and our shareholders."